Lanadelumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lanadelumab. Educational only — not medical advice.
Labeled uses
TAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.
Source: FDA labeling via NIH DailyMed (set 15f99d8c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.